NEW YORK, Oct 28 (Bernama-BUSINESS WIRE) — Medidata, a Dassault Systèmes company, and Boehringer Ingelheim today announced a five-year renewal of their collaboration in the wider area of electronic data capture. The new agreement extends the use of Rave EDC for Boehringer Ingelheim’s clinical trials worldwide and includes myMedidata, Medidata’s suite of innovative patient-facing technologies focused on enhancing patient centricity and diversity in decentralized clinical trials (DCTs).
The agreement adds to Boehringer Ingelheim’s focus on engaging patients in a meaningful way by providing Medidata’s scalable patient-centered capabilities. This includes the myMedidata patient portal, a single-destination web-based platform, which provides access to electronic consent, electronic Clinical Outcome Assessment (eCOA), and myMedidata LIVE video investigator/patient visits.